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Abstract
The crystal structure of the TLR4-MD-2-LPS complex responsible for triggering powerful pro-inflammatory cytokine
responses has recently become available. Central to cell surface complex formation is binding of lipopolysaccharide (LPS) to
soluble MD-2. We have previously shown, in biologically based experiments, that a generation 3.5 PAMAM dendrimer with
64 peripheral carboxylic acid groups acts as an antagonist of pro-inflammatory cytokine production after surface
modification with 8 glucosamine molecules. We have also shown using molecular modelling approaches that this partially
glycosylated dendrimer has the flexibility, cluster density, surface electrostatic charge, and hydrophilicity to make it a
therapeutically useful antagonist of complex formation. These studies enabled the computational study of the interactions
of the unmodified dendrimer, glucosamine, and of the partially glycosylated dendrimer with TLR4 and MD-2 using
molecular docking and molecular dynamics techniques. They demonstrate that dendrimer glucosamine forms co-operative
electrostatic interactions with residues lining the entrance to MD-2’s hydrophobic pocket. Crucially, dendrimer glucosamine
interferes with the electrostatic binding of: (i) the 49phosphate on the di-glucosamine of LPS to Ser118 on MD-2; (ii) LPS to
Lys91 on MD-2; (iii) the subsequent binding of TLR4 to Tyr102 on MD-2. This is followed by additional co-operative
interactions between several of the dendrimer glucosamine’s carboxylic acid branches and MD-2. Collectively, these
interactions block the entry of the lipid chains of LPS into MD-2’s hydrophobic pocket, and also prevent TLR4-MD-2-LPS
complex formation. Our studies have therefore defined the first nonlipid-based synthetic MD-2 antagonist using both
animal model-based studies of pro-inflammatory cytokine responses and molecular modelling studies of a whole dendrimer
with its target protein. Using this approach, it should now be possible to computationally design additional macromolecular
dendrimer based antagonists for other Toll Like Receptors. They could be useful for treating a spectrum of infectious,
inflammatory and malignant diseases.
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Introduction
Dendrimers are a class of spherical macromolecules that
can be distinguished from conventional linear polymers by their
highly branched and symmetrical architecture. Polyamidoamine
(PAMAM) dendrimers are, by far, the best studied of the
commercialised and divergently synthesised dendrimers. Typi-
cally, these dendrimers are available in whole generations (amine
terminated) and half-generations (carboxylic acid terminated) that
are representative of both their size (i.e., diameter in angstroms)
and molecular weight [1–3]. They can be made by controlled
sequential processes to give well defined chemical structures.
Even at low concentrations, the peripheral amine groups of
cationic dendrimers damage cell membranes and lead to cell
toxicity [4]. In contrast, anionic dendrimers have:- (i) physico-
chemical properties that are similar to those of conventional small
molecule drugs; (ii) can be modified to exist as zwitterions at
physiological pH; (iii) have considerable buffering capacity
that makes them physico-chemically ‘‘similar’’ to albumin, and
therefore biocompatible. However, unlike proteins, they:- (a) do
not undergo proteolytic degradation in plasma; (b) are not
immunogenic or otherwise toxic even after repeated administra-
tion by various routes to animals; (c) can be optimized for their
circulation time; (d) show preferential accumulation in tissues
containing inflammatory cells compared to healthy tissue at a
ratio of 50:1 [4]. In addition, the National Cancer Institute’s
Nanotechnology Characterisation Laboratory recently undertook
detailed chemical and toxicological characterization of anionic
PAMAM dendrimers and found them to be both stable and
biocompatible [5]. Taken together, these observations suggest
that anionic dendrimer based drugs could become a new and safe
class of ‘‘synthetic baby-bio’’ (SBB) drugs.
In biologically based experiments, we have already shown that a
generation (G) 3.5 PAMAM dendrimer that was partially modified
with an average of 8 surface glucosamine molecules inhibited
TLR4-MD-2-LPS pro-inflammatory cytokine mediated inflam-
mation in primary human monocytes, dendritic cells, and in a
clinically validated rabbit model of tissue scaring [6]. Molecular
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modeling studies suggested, and experimental studies confirmed,
that the surface loading of a G3.5 PAMAM dendrimer (with an
average of 64 peripheral carboxylic acid groups) could not be
increased beyond an absolute maximum cluster density of 12
evenly spaced surface glucosamine molecules using the divergent
synthesis approach [7]. Frontier molecular orbital theory (FMOT)
and molecular dynamics simulations also showed that the
optimum surface loading and distribution of the zero length
amide bond conjugated glucosamine molecules was determined by
both electronic effects and the different dynamic conformations
adopted by the modified dendrimer during the incremental
addition of glucosamine [7,8]. Importantly, the structural features
and the dynamic behavior of this partially glycosylated dendrimer
showed that its flexibility and polarity changed with the
incremental addition of glucosamine molecules. Notably, these
surface glucosamine molecules remained available for interaction
with the biological target.
Innate immunity provides immediate and efficient defence
against microbial infection and tissue injury by promoting pro-
inflammatory cytokine responses that induce adaptive immune
responses. Toll-like receptors (TLRs), a family of type I trans-
membrane glycoproteins, are central to these vertebrate innate
immune responses because they recognize a broad range of soluble
microbial stimuli on pathogens [9]. They are therefore called
pattern recognition receptors. Their extracellular segments consist
of leucine-rich repeats (LRR) with horseshoe-like shapes [10]. The
binding of soluble agonist ligands leads to protein conformational
change, receptor complex rearrangement, recruitment of specific
adaptor proteins to the intracellular domain, and the initiation of
signalling cascades.
Lipopolysaccharide (LPS – variable MWt.10 kDa) is the outer
membrane glycolipid of Gram-negative bacteria that induces this
innate immune response [11]. It is composed of:- (a) the
hydrophilic polysaccharide core; (b) the solvent exposed hydro-
phobic lipid A component; (c) the O-antigen. Only the lipid A is
required to induce pro-inflammatory cytokine responses. It is
composed of a diphosphorylated b-1,6-linked D-glucosamine
disaccharide linked via amide or ester bonds to 3-hydroxy fatty
acids further substituted by nonhydroxylated 12–14 carbon fatty
acid chains [12]. The cell surface interaction between LPS, TLR4
and MD-2 protein is central to the initiation of pro-inflammatory
cytokine mediated responses. The transport protein CD14 first
collects and delivers soluble LPS to soluble, circulating and
monomeric MD-2 [13,14]. The two phosphorylated glucosamine
residues of lipid A (MWt,2 kDa) bind via electrostatic interac-
tions to the charged entrance (Ser118 {for the 49 phosphate} and
Lys122 {for the 19 phosphate}, and to Arg90 and Lys91) of human
MD-2’s hydrophobic pocket. The diglucosamine and phosphate
groups remain in solution and outside the hydrophobic pocket;
these residues serve to anchor LPS to the entrance of MD-2’s
hydrophobic pocket. This is followed by the lipid chains of LPS
becoming buried in MD-2’s hydrophobic pocket [15]. Subsequent
formation of the human TLR4-MD-2-LPS complex requires:- (a)
hydrophobic interactions between Met85, Leu87, Ile124 and
Phe126 on human MD-2 with Phe436, Phe436, Phe440 and
Phe444 respectively on human TLR4; (b) hydrogen bond
interactions between Arg90 and Gly123 on human MD-2 with
Glu439 and Ser416 respectively on TLR4 [16]. The complex
formed undergoes conformational changes that lead to receptor
complex dimerization, triggering of intracellular signaling events,
and the initiation of pro-inflammatory cytokine production
[17,18]. Low level stimulation of pro-inflammatory cytokine
production is physiologically beneficial for dealing with infections
because it enables the activation of co-stimulatory molecules and
the generation of adaptive immune responses. However, excess
pro-inflammatory cytokine production can become pathological
with serious adverse effects on the host which include septic shock
and death [19].
Previous glycodendrimer based studies have used fully glycosy-
lated molecules; i.e., all of the peripheral groups of the dendrimer
linked to saccharides using a spacer arm derived amide bond
[20,21]. In contrast, our studies are the first to use a partially
glycosylated dendrimer; i.e., a small number of glucosamine
molecules linked to the dendrimer’s surface using a zero length
amide bond. In order to better understand the molecular
mechanism responsible for the ability of partially glycosylated
dendrimers to block pro-inflammatory cytokine production, we
studied their interaction with the LPS recognition system using
molecular modelling techniques. We started from the premise that
their inherent flexibility and, potentially, their size (MWt =
13.6 kDa for a G3.5 PAMAM dendrimer) were important
molecular determinants of their biological properties [6]. Howev-
er, the major limitation for structural biology studies was the
absence of structural data. Although molecular dynamics simula-
tion based study of dendrimer-biomacromolecules interactions is
possible [22,23], we did not have any information about the initial
complex or a starting point for the simulation. We therefore used
molecular docking as a tool to investigate the interactions between
the partially glycosylated dendrimer and the LPS recognition
system. To our knowledge, no previous molecular modelling study
has reported the docking of a whole dendrimer with a protein
target. Our studies therefore provide new insights that should
enable the design of new macromolecules as novel antagonists of
biologically important Toll like Receptor-ligand interactions [24].
Results/Discussion
We first chose and validated molecular docking software
packages that used protein as the target and synthetic macromol-
ecules as the ligand. These are described in the Methods section
and results shown in the Supplementary Figures S1, S2, S3, S4,
Author Summary
Dendrimers are well-defined branched symmetrical mac-
romolecules. In biologically based experiments, we have
shown that a generation 3.5 PAMAM dendrimer whose
surface was modified with 8 surface glucosamine mole-
cules inhibited TLR4 mediated cytokine inflammation in
both primary human cells and a clinically validated rabbit
model of tissue scaring. Molecular dynamics simulations
also showed that these molecules had the flexibility,
surface electrostatic charge, and hydrophilicity to make
them therapeutically useful antagonists. Central to the
TLR4-MD-2-LPS cell surface complex is binding of lipo-
polysaccharide (LPS) to soluble MD-2. We now show that
dendrimer glucosamine forms co-operative electrostatic
interactions with residues lining the entrance to MD-2’s
hydrophobic pocket. These interactions block the entry of
the lipid chains of LPS into MD-2’s hydrophobic pocket
and prevent complex formation. We have therefore
defined the first nonlipid-based synthetic MD-2 antagonist
using both animal model based studies and molecular
modelling studies of a whole dendrimer with its target
protein. Using this approach, it should now be possible to
computationally design additional macromolecular den-
drimer based antagonists for other Toll Like Receptors.
They could be useful for treating a spectrum of infectious,
inflammatory and malignant diseases.
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S5, S6, and S7. Amongst docking softwares that deal with ligands
of increasingly larger size, we found that Patchdock [25], Hex [26]
and Glue [27] could be used. These packages were validated by
reproducing the correct orientations of the ligands in:- (i) the
crystal structure of the mouse TLR4-MD-2 complex (PDB entry:
2z64); (ii) the crystal structure of lipid A complexed with human
MD-2 (PDB entry: 2z59).
We then studied the possible binding modes between the LPS
recognition system and structures of both the biologically inactive
unmodified dendrimer and the biologically active partially
glycosylated dendrimer. By subtracting the results for the
unmodified dendrimer from those for the partially glycosylated
dendrimer, it was possible to determine the contribution of the
surface glucosamine molecules. The first studies involved the
docking of the glucosamine molecules (as the moiety most likely to
contribute to the biological activity of the partially glycosylated
dendrimer) with the human TLR4-MD-2 complex (PDB entry:
3FXI) using Glue. As the binding site for glucosamine is not
known, the whole TLR-MD-2 complex was used as a target by
employing a set of overlapping boxes to increase the resolution of
the docking solution. The results of this series of docking studies
were overlapped and the solutions ranked according to the
interaction energy observed (Figure 1).
The multiple binding sites of glucosamine molecules and their
distribution on the surface of the protein complex meant that they
were not suitable for the use of a ‘‘grow-out’’ strategy to determine
the interactions between these molecules [23]. Nevertheless, it was
notable that the three sites with a high number of poses and with
high favourable interaction energies of the glucosamines with the
TLR4-MD-2 complex were found to be along its beta-6 strand,
the beta-7 strand, and the loop between amino acids Ile94 and
Phe104. They line the opening of MD-2’s hydrophobic pocket
(Figure 1). These results led us to focus our docking studies with
the whole dendrimer on MD-2 as the primary target.
MD-2 is a 160 amino acid glycoprotein with a MWt of 20 kDa
[14]. It represents a class of MD-2–related lipid recognition (ML)
proteins. It is folded into a single domain that consists of two ß
sheets in the immunoglobulin fold. One sheet consists of three
Figure 1. Solutions of the docking studies between the human TLR4-MD-2 complex and glucosamine molecules performed with
GRID protocol. The human TLR4-MD-2 complex is shown with its points of interaction with glucosamine molecules. Blue – human TLR4-MD-2
complex structure represented as ribbons; Red – interacting protein residues and glucosamine molecules with the latter shown as CPK, scaled to the
number of molecules at each spot (0.9 for small spots, 1.7 for medium spots and 2 for large spots). The black ellipse highlights MD-2.
doi:10.1371/journal.pcbi.1002095.g001
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antiparallel ß strands, and the other sheet consists of six
antiparallel strands. Between these sheets is a b cup topology
lipid binding pocket with a volume of 1,710 A˚3 and approximate
dimensions of 15 A˚ by 8 A˚ by 10 A˚. The ß6 and ß7 strands line
the entrance to the hydrophobic pocket. Its shape suggests that it
has evolved to accommodate large and structurally diverse ligands.
Monomeric MD-2 binds to LPS and then forms a stable complex
with TLR4 on the cell surface.
Initially, the interaction between these dendrimers and MD-2
(i.e., shape complementarity) was studied using the protein-protein
interaction softwares Patchdock and Hex. They can carry out rigid
docking only. In the absence of information about the dendrimer’s
bioactive conformation, we had to use different conformations of
the dendrimers for these rigid docking studies. We had already
shown that the partially glycosylated dendrimer was very flexible
by molecular dynamics simulations of fully solvated dendrimers
[7,8]. Initial 3D structures for the simulation were generated using
our ‘‘sequence to conformation’’ method [7,8]. Twenty represen-
tative conformations were then selected from these molecular
dynamics trajectories.
Both the unmodified dendrimer and the dendrimer with 8
surface glucosamines were docked as ligands using Patchdock and
Hex. The unmodified dendrimer was used as a negative control
because it did not alter the biological activity of the TLR4-MD-2-
LPS cell surface receptor complex. The target used was the crystal
structure of human MD-2 (PBD entry: 2e59). For each ligand, the
20 lowest energy solutions were saved (a total of 400 solutions per
dendrimer) and a rebol script implemented in the Vega ZZ
interface used to process the data. The results were analysed in
terms of the total number of interactions between atoms in the
dendrimer and the residues of MD-2 for both the biologically
inactive unmodified dendrimer, and the biologically active
partially glycosylated dendrimer. Although both dendrimers
revealed similar interaction profiles, the partially glycosylated
dendrimer was found to have better shape complementarity, and it
formed more interactions with MD-2. These results showed that
the surface conjugated glucosamines were important for the
dendrimer’s interaction with MD-2.
To investigate if there was specificity in the interactions
observed using Patchdock, the solvent accessible surface area
(SASA) of each residue of MD-2 was determined (Figure 2A), and
plotted alongside the number of interactions for the partially
glycosylated dendrimer (Figure 2B). We found that the overall
negative charge of the unmodified dendrimer’s surface [7,8] did
not favour interactions with the negatively charged surface
residues Glu92, Asp99 and Asp101 that line MD-2’s hydrophobic
pocket. This is the most likely explanation for the lack of biological
activity of the unmodified dendrimer. Comparing the interaction
profiles for unmodified dendrimers with those for partially
glycosylated dendrimers also revealed that the most exposed
residues were not always the ones with the highest number of
interactions with MD-2. This indicated that there was selectivity in
the interactions between the partially glycosylated dendrimer and
MD-2. The same conformations of both dendrimers were then
submitted for docking studies with the Hex shape and electrostat-
ics protocol (Figure 2C). Although there was some similarity
between the interaction profiles for Patchdock and Hex, a larger
number of interactions were detected by Hex for both dendrimer
types and the opening of MD-2’s pocket. Comparing the results
from the two software packages emphasised the importance of
electrostatic interactions between the partially glycosylated
dendrimer and MD-2.
A subtraction of the profile for the partially glycosylated
dendrimer from the unmodified dendrimer showed significant
differences (Figure 3). Most of the interactions of the unmodified
dendrimer were with residues located along the sides and back of
MD-2’s pocket. In contrast, the partially glycosylated dendrimer
had multiple interactions with the entrance to the opening of MD-
2’s pocket. These results suggested that the biologically important
interactions of the partially glycosylated dendrimer were occurring
with residues that lined the entrance to MD-2’s pocket. These
encouraging results from Hex were then normalised with the
energy value determined by multiplying the number of interac-
tions by the corresponding interaction energy for each solution.
When interaction energies were also taken into account, the
differences between the unmodified dendrimer and the partially
glycosylated dendrimer became even more marked for the residues
lining the entrance to MD-2’s hydrophobic pocket (Figure 4).
The surface residues lining the entrance of human MD-2’s
pocket that have been shown to have a key role in the electrostatic
binding of LPS are Arg90, Lys91, Ser118 and Lys122 (Figure 5A)
[15,17]. The biologically active partially glycosylated dendrimer
showed the largest number and the strongest interactions with
several of the residues lining the entrance to MD-2’s pocket.
Several of these residues are also important for the binding of LPS
to MD-2. The residues with the highest normalized interaction
values were Lys91, Tyr102, Arg106, Asn114 and Ser118. Several
other residues, with lower interaction values, also contributed
significantly to the co-operative binding of the partially glycosy-
Figure 2. Interaction studies between the dendrimers and
human MD-2. (A) Solvent accessible surface area (SASA) was
determined for each human MD-2 residue; (B) Docking studies
performed with Patchdock; (C) Docking studies performed with Hex.
Black columns – dendrimer modified with 8 glucosamines. Grey
columns – unmodified dendrimer.
doi:10.1371/journal.pcbi.1002095.g002
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lated dendrimer to human MD-2; they were Arg96, Ser98,
Lys109, Thr112 and Thr116 (Figures 5B & C).
To assess the dynamic behaviour of these interactions, and to
determine whether using docking software designed for studying
protein-protein interactions was affecting the results, a 4.8 ns
molecular dynamics simulation of the partially glycosylated
dendrimer complexed with MD-2 was performed in explicit
solvent. The starting conformation used was one of the most stable
docking solutions obtained with Hex. In this docking solution
structure, the partially glycosylated dendrimer was located directly
in front of MD-2’s pocket with three of the glucosamine molecules
in close proximity at 0 ns (Figure 6). As the simulation progressed,
the partially glycosylated dendrimer moved away from MD-2 in
order to rearrange its peripheral branches. This changed the
number of glucosamine molecules facing MD-2’s pocket. From
2.4 ns until the end of the simulation (i.e., 4.8 ns), the partially
glycosylated dendrimer underwent further conformational chang-
es such that 4 glucosamine molecules were consistently in close
contact (i.e., 1.3 A˚) with the entrance of MD-2’s pocket (Figure 6).
In addition, the entrance to this pocket was occluded by the
partially glycosylated dendrimer during the entire 4 ns simulation.
This is shown in Figure 7 by the semi-transparent pink colour
which represents the partially glycosylated dendrimer’s structure
during its interaction with the entrance of MD-2’s hydrophobic
pocket.
The affinity of the partially glycosylated dendrimer for human
MD-2 was demonstrated by the increased number of close
contacts (i.e., 1.3 A˚) between these two molecules (Figure 8) that
involved both the glucosamine molecules and several of the
dendrimer’s peripheral carboxylic acid branches (Figure 9). These
electrostatic interactions occluded the entrance to human MD-2’s
hydrophobic pocket and blocked access of the lipid chains of
LPS. When taken with our previous observations that partially
glycosylated dendrimers are both flexible and dynamic, this meant
that conformational changes could induce shape complementarity
[7,8]. This enabled the dendrimer’s surface glucosamine molecules
to block the entrance of human MD-2’s pocket. Additional co-
operative electrostatic interactions with some of the dendrimer’s
free carboxylic acid branches follow. Collectively, they block the
entry of the lipid chains of LPS into human MD-2’s pocket, and
also prevent TLR4-MD-2-LPS cell surface complex formation.
This is shown schematically in Figure 10. The biologically
important outcome is that the pro-inflammatory cytokine cascade
is not initiated.
Figure 3. Difference between the number of interactions of human MD-2 with the unmodified dendrimer and the partially
glycosylated dendrimer. Black columns – docking study performed with Hex; Grey columns – docking study performed with Patchdock. The
Patchdock results showed a larger number of interactions with human MD-2 along its whole sequence. The Hex results showed a clear preference for
interactions with residues lining the entrance to human MD-2’s hydrophobic pocket (i.e., residues 84 to 127).
doi:10.1371/journal.pcbi.1002095.g003
Figure 4. Number of interactions between human MD-2 and ligands normalised to the energy values for each interaction. The graph
shows the difference between the number of interactions with human MD-2 of the unmodified dendrimer and the partially glycosylated dendrimer
from the docking study performed with Hex after it was normalised for the energy value for each interaction. The graph also shows the residues that
line the opening of human MD-2’s hydrophobic pocket. The secondary structure of human MD-2 is shown with the solid grey arrows representing
the ß6 (Pro88 to Ile94) and ß7 strands (Val113 to Ser120). The grey box represents the a-helix (Phe104 to Lys109). The lines represent the loops.
doi:10.1371/journal.pcbi.1002095.g004
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Lipid A is the primary immuno-stimulatory core of LPS.
Although diverse across bacterial species, its di-glucosamine portion
is universally conserved. Variants of LPS can be discriminated by
the TLR4-MD-2 complex as being either endotoxic (i.e., agonist) or
anti-endotoxic (i.e., antagonist) or partial antagonist/partial agonist.
For example, lipid A (with six acyl chains) from Escherichia coli is a
potent agonist of cytokine production in human and mouse
macrophages [28]. The lipid chains form co-operative interactions
with hydrophobic residues in MD-2’s pocket. However, its
precursor, lipid IVa, which has only four acyl chains, is an
antagonist in human macrophages but an agonist in mouse
macrophages. These lipid chain based differences have been used
to define the central role of the di-glucosamine moiety with respect
to the initial binding of LPS to MD-2, and the subsequent formation
of the TLR4-MD-2-LPS complex [17]. Furthermore, the binding of
all agonists to MD-2 induces a conformational change in MD-2, but
the fact that such structural change does not occur when an
antagonist binds to MD-2 has provided the basis for the structure-
function based development of new molecules to modify this
protein’s biological activity. In this context, the key observation has
been that underacylated lipid A functions as an antagonist by
occupying MD-2 and not inducing the conformational change in
this protein required to trigger TLR4 activation and oligomerisation
[29]. The most advanced antagonist in development is eritoran (or
e5564). It is a synthetic di-glucosamine and lipid based molecule
that is derived from the lipid A structure of the nonpathogenic LPS
of Rhodobacter sphaeroides [30]. It binds and blocks the entry of LPS
into MD-2’s pocket and thereby prevents formation of the TLR4-
MD-2-LPS cell surface receptor complex. Unlike lipid A, eritoran’s
antagonist activity depends solely upon electrostatic interactions
with Lys122 and Lys125 on the b-7 strand of MD-2.
These published observations about the lipid A based bioactive
site of LPS make our results surprising because they suggested
that the presence of highly hydrophobic lipidic chains was a
prerequisite for any agonist or antagonist to bind effectively to
MD-2 [31]. However, our results show, for the first time, that the
presence of lipidic chains is not an absolute requirement for an
MD-2 antagonist or partial antagonist. Our molecular docking
studies also show that these partially glycosylated dendrimers
bound to human MD-2 and interfered with the electrostatic
binding of:- (i) the 49phosphate on the di-glucosamine of LPS to
Ser118 on MD-2; (ii) LPS to Lys91 on MD-2; (iii) the subsequent
binding of TLR4 to Tyr102 on the MD-2-LPS complex. These
three residues line the hydrophilic entrance of MD-2’s hydropho-
bic pocket (Figure 5). Additional polyvalent interactions between
several other human MD-2 surface residues [i.e., Arg96, Ser98,
Arg106, Lys109, Thr112, Asn114 and Thr116 (Figures 5b & c)]
and several of the partially glycosylated dendrimer’s peripheral
Figure 5. Crystal structure of human MD-2 with PDB entry 2E56 displayed as its electrostatic potential surface. (A – left hand side
figure):- Residues Arg90, Lys91, Ser118 and Lys122 on human MD-2 form electrostatic interactions with lipid A. The interaction of Lys122 and Arg90
with the hydrophilic moiety of lipid A tethers LPS to human MD-2’s cavity [15]. The 49 phosphate on lipid A’s first glucosamine binds to Ser118 and
the 19 phosphate on lipid A’s second glucosamine binds to Lys122. In addition, Tyr102 is crucial for the subsequent hydrogen bond interaction of the
human MD-2-LPS complex with human TLR4 [55]. (B – middle figure):- The residues Lys91, Arg96, Tyr102 and Ser118 form electrostatic interactions
with the partially glycosylated dendrimer. (C – right hand side figure):- Human MD-2 is shown in its ‘‘top right’’ orientation. The residues Ser98,
Tyr102, Arg106, Lys109, Thr112, Asn114 and Thr116 form electrostatic interactions with the partially glycosylated dendrimer. These residues, which
border the entrance of human MD-2’s hydrophobic pocket, are labelled in the figures.
doi:10.1371/journal.pcbi.1002095.g005
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carboxylic acid branches (Figure 9) enables it to position itself so
that it always occludes the entrance to MD-2’s pocket (Figure 10).
This blocks the entry of the lipid chains of LPS into human MD-
2’s pocket and explains the molecule’s antagonist activity.
Our results also suggest that the interaction of the G3.5 partially
glycosylated dendrimer with human MD-2 is specific. This
conclusion is supported by the experimental biological data that
only the TLR4 mediated pathway is affected by this molecule [6].
It should be noted that the dendrimer’s surface glucosamines
interact in a dynamic manner with several of the surface residues
of MD-2. This promiscuity of MD-2 is an important evolutionary
feature and reflects the need of MD-2 to be able to recognise all of
the diverse LPS structures synthesised by individual species of
Gram negative bacteria. MD-2’s promiscuity extends to the
binding of endogenous host derived ligands that act as alert signals
for tissue injury, such as enzyme derived fragments of hyaluronan
from the extracellular matrix [32].
Our previous modelling studies suggested that a dendritic
architecture was important for this molecule’s biological activity
[7,8]. In addition, our previous biological studies [6] were
preceded by unpublished observations with smaller generations
of partially glycosylated PAMAM dendrimers; these molecules did
not have the desired biological activity. As the synthesis of higher
generation dendrimers (e.g., G4.5 and higher) is both expensive
and leads to considerable polydispersity of the molecule, their
biological activity was not tested. However, our findings, based
upon the detailed modelling of the G3.5 partially glycosylated
dendrimer, suggest that larger generations of these molecules
should be biologically active because they explore a similar
conformational space to the G3.5 partially glycosylated dendrimer.
We have also been investigating the use of other polyanionic
dendrimers with both different cores and branching units, but with
the same carboxylated surface. Having successfully glycosylated
different generations of these dendrimers, we have found that only
some of them exhibit the biological activity required (paper in
preparation). We are coming to the conclusion that the main
difference between the biologically active partially glycosylated
dendrimers and biologically inactive molecules lies in their
flexibility which, in turn, leads to changes in both their peripheral
conformation and their surface electrostatic properties.
Several years ago, we came to recognize the potential therapeutic
importance for making polyvalent medicines because of our studies
into the receptor-ligand interactions that mediate HIV-1 entry into
cells [33,34]. We, and others, then realized that some aspects of cell
surface mediated immuno-regulation depended upon co-operative
electrostatic interactions between carbohydrates and proteins
Figure 6. Snapshots of a molecular dynamics simulation of the partially glycosylated dendrimer with human MD-2 obtained with
Hex. These figures show the molecule blocking the entrance to human MD-2’s hydrophobic pocket. Top left and across the page to top right:- 0 ns;
0.8 ns and 1.6 ns. Bottom left and across the page to bottom right:- 2.4 ns; 3.2 ns and 4 ns. Human MD-2 is displayed as ribbons, the partially
glycosylated dendrimer as tube, and the surface glucosamines as CPK.
doi:10.1371/journal.pcbi.1002095.g006
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[35,36]. This has now been shown to be the case for the receptor-
ligand interaction between TLR4 and LPS by the demonstration of
an exponential increase in binding affinity [37]. Another example is
the observation that four oligosaccharides are required for a
functional immunological response to inhibit the LPS - DC SIGN
cell surface interaction; N-acetyl-glucosamine-galactose-glucos-
amine and fucose-glucosamine-N-acetylglucosamine are required
rather than N-acetyl-glucosamine or galactose on their own [38].
Our proof-of-concept studies have therefore demonstrated that
it is possible to design a hyperbranched macromolecule with a pre-
defined biological activity. The crucial advantage of our approach
is that it avoids the expensive and complex chemistry associated
with preparing oligosaccharides. This is because we can system-
atically modify the chemical functionality of the peripheral groups
of dendrimers for a pre-defined biological activity using the
simplified chemistry of monosaccharides to present aminosacchar-
ides to cell surface receptors. As a result, medicinal grade product
synthesis becomes a realistic goal for undertaking cost-effective
clinical trials. Protein based medicines have already achieved this
for macromolecules of .20 kDa by interacting with multiple cell
surface receptors. Therefore, the use of dendrimeric structures of
2–5 kDa resolves two major obstacles that have impeded the
therapeutic progression of synthetic macromolecules:- (i) excessive
structural heterogeneity and poor control of molecular weight
distribution; (ii) side-effects from in vivo activation of both
complement and coagulation pathways [33,34].
Our approach also enables, for the first time, the adoption of
existing molecular modelling software (originally designed for
studying protein-protein interactions) for the study of the
interactions of synthetic macromolecules with biologically impor-
tant proteins. Taken together with our previous modelling studies,
which rationalised the effects of pegylation on the structure and
biological activity of both proteins and peptides [39–43], we now
believe that the principles and computational approaches that we
have described could be applied more broadly to achieve proof-of-
concept for other macromolecular structures.
We have also provided new insights into the interactions
between a synthetic hydrophilic macromolecule and a protein
usually targeted by hydrophobic molecules. These observations,
coupled with an increasing number of recently published studies
that underscore the important functional role of electrostatic
interactions in TLR-ligand interactions, should facilitate the
design of novel macromolecules that are both chemically well
defined and biologically useful for the therapeutic manipulation of
Figure 7. Surface contact area between human MD-2 and the partially glycosylated dendrimer. (A) 0 ns, (B) 1.6 ns, (C) 2.4 ns. Left –
frontal view of human MD-2. Right – side view of human MD-2. The human MD-2 surface is shown in grey, the partially glycosylated dendrimer’s
surface is shown in pink with 80% transparency, and their contact surface area is shown in green.
doi:10.1371/journal.pcbi.1002095.g007
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important TLR based immuno-pathological pathways [44]. This
is because the binding orientations amongst all TLRs are similar
even though the residual interactions with their ligands are
specific. There is also an increasing body of evidence to suggest
that a network of hydrogen bonds controls the precise positioning
of the ligand in a TLR, and that it is the molecule’s precise
positioning that determines the specificity of TLR-ligand complex
mediated signalling events [45,46].
Established drugs are typically small molecules with a MWt of
,500 Da. Biopharmaceuticals with a MWt of .20 kDa that are
agonists of naturally occurring biological pathways are already on
the horizon as important new medicines. Designing and delivering
a novel generation of well defined chemically synthesised
molecules with MWts of 2–5 kDa that mimic important biological
properties is the new challenge for chemical-biologists. We
propose that chemically optimised dendrimers with well defined
chemical and biological properties (which we also propose could
be called ‘‘synthetic baby bios’’ (SBBs)) can now be designed using
the computational biology approaches described. These molecules
could be useful for treating a spectrum of infectious, inflammatory
and malignant diseases.
Methods
Validation of Patchdock and Hex softwares
Hex and Patchdock are two different software packages
developed for the study of protein-protein interactions. Their
algorithms and scoring functions are different. Patchdock reads
each structure and transforms it into Conolly surface representa-
tions [47,48] that include flat, concave and convex patches [49].
The complementarities between patches are assessed and then
given a scoring function which takes into account both shape
fitting and desolvation energy; i.e., energy required to break
molecule-solvent interactions. The results are cluster based on the
RMSD values of each transformation [49].
The crystal structure of the mouse TLR4-mouse MD-2 complex
(PBD entry: 2z64) was used to evaluate whether the software could
reproduce the structure of the complex. The mouse TLR4-mouse
MD-2 complex was used because, at that time, there was no
crystal structure for the human cell surface receptor complex.
For the negative controls, the target used was the same as that
used for the positive control docking experiments; i.e., mouse
TLR4 from the X-ray structure with PDB entry 2z64. However,
the ligand was not mouse MD-2 from the same crystal structure
but instead human MD-2 from the two different crystal structures
available (i.e., PDB entries: 3FXI and 2e56). Docking for these
negative control experiments was carried out using the same
parameters as were used for the positive control experiments.
In the first experiment to dock TLR4 with MD-2, all of the
oligosaccharides found in the original PDB entry file were
removed. This resulted in a best fit that showed MD-2 interacting
with TLR4 on the inside of the horseshoe (Supplementary Figure
S1-A; brown image) rather than sitting on top of the TLR4
extracellular domain. When the change in docking target was
changed to a TLR4 possessing all its oligosaccharides, this
produced a good superimposition between the crystal structure
and the docking result (Supplementary Figure S1-B).
A third experiment was performed keeping only the oligosac-
charides inside the horseshoe. This also showed that the MD-2
from the crystal structure overlay the docked MD-2 (Supplemen-
tary Figure S1-C). This result indicated that the presence of sugar
Figure 8. Interactions observed during a 4.8 ns molecular
dynamics simulation of the partially glycosylated dendrimer –
human MD-2 complex. Red – number of contacts of 1.3 A˚ between
the dendrimer’s surface glucosamine molecules and human MD-2. Blue
– number of contacts of 1.3 A˚ between the partially glycosylated
dendrimer (taking the molecule in its entirety) and human MD-2. Green
– number of intermolecular hydrogen bond contacts between the
partially glycosylated dendrimer (taking the molecule in its entirety) and
human MD-2. Taken together, these results show that the affinity of the
partially glycosylated dendrimer for human MD-2 involved both the
dendrimer’s surface glucosamine molecules and several of its peripheral
carboxylic acid branches. Notably, these hydrogen bond interactions
increased with time. This enabled the partially glycosylated dendrimer
to block the entrance to human MD-2’s hydrophobic pocket and
thereby prevent access of the lipid chains of LPS.
doi:10.1371/journal.pcbi.1002095.g008
Figure 9. Interaction of the partially glycosylated dendrimer’s surface with human MD-2’s surface. Residues shown in red are ,1.3 A˚
away from the surface of human MD-2. Glucosamine residues are shown in ball and stick configuration. (A) Side view of human MD-2’s pocket; (B)
frontal view of human MD-2’s pocket.
doi:10.1371/journal.pcbi.1002095.g009
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molecules inside the horseshoe was crucial for the correct
positioning of MD-2 in the TLR4-MD-2 complex.
In the negative control experiments (Supplementary Figure S2),
the lack of shape complementarity between the mouse and human
regions critical for the TLR-4 and MD-2 interaction was used to
confirm that a cross-species analysis (i.e., mouse TLR4 with
human MD-2) did not reproduce the orientation of mouse TLR4
with mouse MD-2. It was also notable that human MD-2, taken
from the crystal structure of the human TLR4-human MD-2
complex, gave a better solution that the use of human MD-2
complexed to lipid A from the crystal structure with PDB file entry
2z59. These negative control experiments confirmed that
Patchdock was suitable for more detailed studies once the target
molecules had been correctly defined.
The Hex software package was developed for protein and
nucleic acid interaction studies. It also allows modelling of small
ligand-protein interactions using rigid docking. Hex is a fast
Fourier transform (FFT) docking correlations based programme
that uses soft polar Fourier correlations to minimise the
computational time required to explore the Cartesian space
[50,51]. The protein’s molecular surfaces are represented by an
internal and an external ‘‘skin’’ that are each represented by a
Fourier series, and comprise radial and spherical harmonic basis
functions [50]. The electrostatics contribution is optional, when
present, and is only taken into account in the final search [52]; it
has a small weighting in the final scoring function. The resulting
structures are ordered from lowest to highest energy, and then
clustered with a 3 A˚ threshold for the main chain Ca - Ca RMSD
values [52].
The same crystal structure of the mouse TLR4-mouse MD-2
complex (PDB entry: 2z64) was used to evaluate whether the
software could reproduce the structure of this complex. The
influence of the ‘‘shape only’’ parameters versus ‘‘shape and
electrostatics’’ parameters was also assessed. Since Patchdock
revealed the importance of the presence of the oligosaccharides
inside TLR4’s horseshoe, these were considered in the docking
process with Hex.
The docking results of the mouse TLR4-mouse MD-2 complex
showed that the Hex shape only protocol software was inadequate
for describing the system correctly (Supplementary Figures S3-A
and S3-C). If a contribution from electrostatics (even with a
smaller weighting) was taken into account, the docking reproduced
the crystal structure albeit with a small deviation, but maintained
the correct interaction site of TLR4 with MD-2 (Supplementary
Figure S3-B).
These negative control experiments with Hex showed that the
lack of shape complementarity between the human and mouse
regions of MD-2 critical for TLR4-MD-2 complex formation (i.e.,
a cross-species analysis using mouse TLR4 and human MD-2) did
not reproduce the orientation of mouse TLR4 in relation to mouse
MD-2 (Supplementary Figure S4). Therefore, these modelling
results were consistent with the biological observation that:- (i) pro-
inflammatory cytokines are produced when HEK293 cells are
transfected with human TLR4 and human MD2 and then
stimulated with LPS; (ii) pro-inflammatory cytokine production
does not occur when HEK293 cells are transfected with human
TLR4 and mouse MD2 and then stimulated with LPS [53]. There
is therefore a lack of shape complementarity between the human
and mouse regions of MD-2 critical for the TLR4-MD-2
interaction. These observations led us to conclude that the Hex
shape and electrostatics protocol was the most suitable for our
further studies.
Validation of GRID software
For a better understanding of the contribution of electrostatics
in the interaction of the dendrimer and the glycosylated dendrimer
with the LPS recognition system, GRID software was used. GRID
is a calculation based procedure [54]. It enables the determination
of the energetically favourable binding sites on a molecule whose
structure is known. GRID results can be visualized with the Gview
application. It allows visualization of molecular interaction fields,
GRID energy contributions due to atoms of the target, and
molecular structures with distances, torsion, and dihedral angles.
Glue is a GRID docking programme that is capable of finding
potential interaction sites between a molecule, set as ‘‘target’’, and
a small molecule set as ‘‘ligand’’. It requires the input of both the
target and the 3D structures of the ligand. Its scoring function
takes into account steric repulsion energy, electrostatics contribu-
tion, a dry parameter (which accounts for hydrophobic energy),
and an additional hydrogen bonding charge reinforcing param-
eter.
The system used for Grid validation was human MD-2-lipid
IVa (PDB entry: 2z59). The GRID results for the structure of the
human MD-2-lipid IVa complex were very similar to the crystal
structure of lipid A with human MD-2’s hydrophobic pocket,
with respect to both position and conformation (Supplementary
Figure S5).
In addition, the number of interactions between the residues of
human MD-2 and the atoms of the partially glycosylated
dendrimer (as summarised from the 400 solutions of the docking
study performed with Hex) were plotted together with the number
of interactions between the residues of human MD-2 and the
single lipid A structure obtained from the crystal structure of its
complex with MD-2 [PDB entry: 2z59] (Supplementary Figure
S6). This highlighted:- (a) the hydrophobic nature of the binding of
the acyl chains of lipid A to residues 27 to 37 of human MD-2; (b)
the hydrophilic nature of the binding of the partially glycosylated
dendrimer to the entrance of human MD-2’s hydrophobic pocket
{residues 84 to 127}; and (c) the competitive nature of the binding
of these two molecules to the entrance of human MD-2’s
hydrophobic pocket.
The negative control experiments used sucrose and maltose as
ligands. In biological experiments, we first confirmed that these
two ligands did not compete with the binding site of LPS on
human MD-2 (unpublished observations). They were then docked
against the same target; i.e., human MD-2 from the PDB file entry
2e59. The results with maltose and sucrose confirmed that their
binding sites were distant to the binding site of the lipid A of LPS
to human MD-2 (Supplementary Figure S7). Based on these
Figure 10. Schematic representation of the proposed mecha-
nism of action of partially glycosylated dendrimers on human
MD-2. Green – hydrophobic residues. Red and blue – hydrophilic
regions.
doi:10.1371/journal.pcbi.1002095.g010
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results, we considered GRID to be the most suitable software for
our further studies.
Crystal structures
The structures of the proteins used for the docking studies were
obtained through the RCBS website (www.rcsb.org). The crystal
structures of the mouse TLR4-mouse MD-2 complexed with
eritoran (PDB entry: 2z64), and the human MD-2 complexed with
lipid IVa (PBD entry: 2e59) were used for validation of the docking
software. The complex of human TLR4-human MD-2 (PDB
entry: 3FXI) was used as a target for the docking studies; the non-
glycosylated MD-2 without ligand was extracted from the crystal
structure (PDB entry: 3FXI) and loaded into Maestro. Hydrogen
atoms were then added and a molecular dynamics simulation
performed with Desmond. The fully solvated system was built
using the SPC solvation model and the size of the box determined
automatically by creating a 10 A˚ buffer around the system being
simulated. The molecular dynamics simulation was performed for
200 ps at 300K and 1.03 bar. These included structure
minimisation and relaxation steps. The final structure was used
as a target in the docking studies performed with Patchdock and
Hex.
Docking studies with GRID22 software
Greater (Molecular Discovery Ltd) was used to generate the
‘‘.kout’’ files for all of the molecules studied. Glue (Molecular
Discovery Ltd) was used for docking studies. For the docking
process itself, all available probes were selected to generate
molecular interactions fields (MIFs). A maximum of 100 binding
sites were used with an energy cut-off of 2100 kCal/mol. The
maximum iterations value was set to 120. For ligand flexibility, 5
rotatable bonds were allowed and the electrostatic term was
included for the calculation of the interaction energies. Glucos-
amine was docked with the human TLR4-MD-2 complex (PDB
entry: 3FXI) using several overlapping target volumes defined as a
box with a side of 30 A˚.
Docking studies with Patchdock
Patchdock was used with all default parameters, except that the
maximum surface overlap had to be changed to the lower value of
22. The 20 lowest energy structures were saved as PDB files for
further studies. The same protocol was used to dock mouse TLR4
with mouse MD-2 for validation, and to compare it with the
crystal structure (PDB entry: 2z64). Once validated, the protocol
was used to study the interactions of the G3.5 PAMAM dendrimer
and the G3.5 partially glycosylated PAMAM dendrimer with:- (i)
the human TLR4 - human MD-2 complex; (ii) human MD-2.
Docking studies with Hex 5.0
The docking studies carried out with Hex involved the use of
two different protocols. The first was a shape based protocol. The
second included both shape and electrostatics based protocols. All
other parameters were the same for both protocols and were set to
their default values. The scan steps were set to 0.75 with 2
substeps. The order of the docking correlation was set to 25 for the
steric scan, and 25 for the fine search. The grid size was set to 1
and 100 solutions. Of these, the representative structures of the
first 20 clusters were saved as PDB files for further analysis. The
studies of the unmodified dendrimer and the partially glycosylated
dendrimer against human MD-2 and the human TLR4-human
MD-2 complex were performed with the shape and electrostatics
protocol. Twenty different conformations of each biologically
inactive and active molecule were used as ligands.
Data analysis of the docking solutions
For the visualisation of the outputs from the docking studies and
to generate images, Discovery Studio Visualise v2.5 (Accelerys)
was used. To process the 800 solutions resulting from the docking
of the unmodified and modified molecules with human MD-2, a
rebol script implemented in VegaZZ was used. This script
reported every atom in the dendrimer that was at a distance of
,3 A˚ from an atom in human MD-2. The resulting files were
exported to Microsoft Excel and plotted as graphs. For energy
scaling of the interactions, the number of interactions from each
solution was multiplied by their energy value. The energy
calculations were only performed for the Hex solutions.
Molecular dynamics simulations
Initial conformations of the unmodified dendrimer and the
partially glycosylated dendrimer were generated with X-PLOR
using our ‘‘sequence to conformation’’ method [7,8]. These
structures and the complex of human MD-2 with the partially
glycosylated dendrimer were obtained from a docking solution
using Hex imported into Maestro, and then set up for molecular
dynamics simulation with Desmond. The fully solvated systems
were built using the SPC solvation model, and the size of the box
determined automatically by creating a 10 A˚ buffer around the
system being simulated. The molecular dynamics simulations were
performed for 4.8 ns at 300K and 1.03 bar. These included
structure minimisation and relaxation steps. Snapshot structures
were recorded every 4.8 ps. The contact surface areas between the
partially glycosylated dendrimer and human MD-2 were deter-
mined from selected frames of the 4.8 ns trajectory using the
Chimera software package (www.cgl.ucsf.edu/chimera), having set
the cut-off for van der Waal’s interactions to 4 A˚. The
representative conformations of the unmodified dendrimer and
the partially glycosylated dendrimer were obtained by trajectory
analysis using Vega ZZ.
Supporting Information
Figure S1 Results of the interaction study of mouse
TLR4 extracellular domain and mouse MD-2 with
Patchdock. Using as target – (A) mouse TLR4 in the PDB file
entry 2z64 without any of the saccharides co-crystallised. Light
blue – mouse TLR4; Dark blue – mouse MD-2 from the crystal
structure; Brown – mouse MD-2 from the docked structure. (B)
mouse TLR4 in the PDB file entry 2z64 with all of the saccharides
co-crystallised. Purple – mouse TLR4; Dark blue – mouse MD-2
from the crystal structure; Brown – mouse MD-2 from the docked
structure. (C) mouse TLR4 PDB file entry with only those
saccharides inside the horseshoe that are close to where the
interaction with mouse MD-2 is expected, and as co-crystallised
and present in the PDB file entry 2z64. Light blue – mouse TLR4;
Dark blue – mouse MD-2 from the crystal structure; Brown –
mouse MD-2 from the docked structure.
(TIF)
Figure S2 Negative control results obtained for the
interaction study of the TLR4 extracellular domain and
MD-2 with Patchdock. (A) Docking results for mouse TLR4
with human MD-2 as complexed to human TLR4 (PDB entry:
3XFI). Light blue – mouse TLR4; Green – human MD-2 from the
crystal structure of the human MD-2-human TLR4 complex. (B)
Docking results for mouse TLR4 with human MD-2 as complexed
with lipid A (PDB entry: 2E56). Light blue – mouse TLR4; Lime
green – human MD-2 from the crystal structure of the human
MD-2-lipid IVa complex.
(TIF)
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Figure S3 Results obtained for the interaction study of
the mouse TLR4 extracellular domain and mouse MD-2
with Hex 5.0. Using as target – (A) Crystal structure from the
mouse TLR4-mouse MD-2 complex (PDB entry: 2Z64). Light
blue – mouse TLR4; Dark blue – mouse MD-2 from the crystal
structure. (B) Docking results obtained for the mouse TLR4-mouse
MD-2 complex taking into account both shape and structure.
Light blue – mouse TLR4; Dark blue – mouse MD-2 from the
crystal structure; Brown – mouse MD-2 from the docked structure.
(C) Docking results for the mouse TLR4-mouse MD-2 complex
with a shape only protocol. Light green – mouse TLR4; Purple –
mouse MD-2 from the crystal structure; Purple – mouse MD-2
from the docked structure. The saccharides in TLR4’s horseshoe
are hidden for clarity.
(TIF)
Figure S4 Negative control results obtained for the
interaction study of the TLR4 extracellular domain and
MD-2 with Hex 5.0. (A) Docking results for the mouse TLR4-
human MD-2 complex. Light blue – mouse TLR4; Green – human
MD-2 from the crystal structure of the human TLR4-human MD-2
complex. (B) Docking results for the mouse TLR4-human MD-2
complex. Light blue – mouse TLR4; Lime green – human MD-2
from the crystal structure of the human MD-2-lipid IVa complex.
The saccharides in TLR4’s horseshoe are hidden for clarity.
(TIF)
Figure S5 GRID protocol validation. (A) Crystal structure of
the human MD-2-lipid IVa complex (PDB entry: 2e59). (B)
Structure obtained with Glue for the same complex.
(TIF)
Figure S6 Interaction studies of human MD-2 with lipid
A and with the partially glycosylated dendrimer. Number
of interactions of ,6 A˚ between human MD-2 residues and the
atoms of:- (i) lipid A from the crystal structure of this complex
(PDB entry: 2e59) as shown in red; (ii) the partially glycosylated
dendrimer [as summarised from the 400 solutions of the docking
study performed with Hex] as shown in black.
(TIF)
Figure S7 Negative control experiments for GRID
protocol validation. (A) Docking results for maltose and human
MD-2. (B) Docking results for sucrose and human MD-2. These
experiments confirmed that the binding sites for maltose and
sucrose on human MD-2 were distant to the binding site of the
lipid A of LPS.
(TIF)
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